文献速递炎症性肠病

英夫利西单抗与阿达木单抗在827例生物制剂初治克罗恩病患者中的比较:一项基于丹麦人群的队列研究

Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-14

该研究基于丹麦全国登记数据,纳入2005-2014年间首次使用英夫利西单抗或阿达木单抗的2908例成人克罗恩病患者,经2:1倾向评分匹配后比较315例阿达木单抗与512例英夫利西单抗治疗患者。中位随访2.3年,两组克罗恩病相关住院和重大腹部手术率无显著差异,阿达木单抗组全因住院率较低(HR 0.74),严重感染需住院发生率无显著差异。

要点

  • 倾向评分匹配后,阿达木单抗组全因住院率低于英夫利西单抗组(HR 0.74,95%CI 0.56-0.97)。
  • 两组克罗恩病相关住院(HR 0.81)、重大腹部手术(HR 1.24)和严重感染(HR 1.06)均无显著差异。
  • 在生物制剂单药或联合免疫调节剂亚组中,上述结果保持稳定。

核心结论

  • 在生物制剂初治的克罗恩病患者中,阿达木单抗与英夫利西单抗在有效性和安全性方面无显著差异。

研究设计与样本

  • 基于丹麦全国登记数据的倾向评分匹配队列研究,纳入2005-2014年间2908例首次使用阿达木单抗或英夫利西单抗的成人克罗恩病患者,经2:1倾向评分匹配后分析315例阿达木单抗和512例英夫利西单抗治疗患者。

主要发现

  • 中位随访2.3年,阿达木单抗组与英夫利西单抗组克罗恩病相关住院率无显著差异(HR 0.81,95%CI 0.55-1.20)。
  • 两组重大腹部手术率无显著差异(HR 1.24,95%CI 0.66-2.33)。
  • 阿达木单抗组全因住院率低于英夫利西单抗组(HR 0.74,95%CI 0.56-0.97)。
  • 两组严重感染需住院发生率无显著差异(HR 1.06,95%CI 0.26-4.21)。
  • 在生物制剂单药治疗亚组中,全因住院HR 0.75(95%CI 0.53-1.05)、克罗恩病相关住院HR 0.82(95%CI 0.51-1.32)、腹部手术HR 1.47(95%CI 0.63-3.47);联合免疫调节剂亚组中,全因住院HR 0.70(95%CI 0.44-1.11)、克罗恩病相关住院HR 0.80(95%CI 0.42-1.52)、腹部手术HR 1.02(95%CI 0.39-2.64)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are conflicting data on comparative effectiveness of adalimumab and infliximab in patients with Crohn's disease (CD). AIMS: To compare the effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD, in a nationwide register-based propensity score-matched cohort study in Denmark. METHODS: A total of 2908 Danish adults with CD had been treated with adalimumab or infliximab as their first biologic agent between 2005-2014. By Cox regression, we compared rates of all-cause hospitalisation, CD-related hospitalisation, major abdominal surgery and serious infections after variable 2:1 propensity score matching, accounting for baseline disease characteristics, healthcare utilisation and use of CD-related medications. RESULTS: After propensity-score matching, we included 315 adalimumab- (34.9 ± 12.9 years, 41.9% males) and 512 infliximab-treated (33.6 ± 12.6 years, 40.8% males) patients, with median disease duration 4.0 years; 36.9% had prior abdominal surgery. Over a median follow-up 2.3 years after starting biological therapy, there were no significant differences in rate of CD-related hospitalisation (hazard ratio [HR], 0.81 [95% CI, 0.55-1.20]) or major abdominal surgery (HR, 1.24 [0.66-2.33]) between adalimumab- and infliximab-treated patients, though rate of all-cause hospitalisation was lower in adalimumab-treated patients (HR, 0.74 [0.56-0.97]). There was no significant difference in incidence of serious infections requiring hospitalisation (HR, 1.06 [0.26-4.21]). These results were stable in patients treated with biological monotherapy (all-cause hospitalisation: HR, 0.75 [0.53-1.05]; CD-related hospitalisation: HR, 0.82 [0.51-1.32], abdominal surgery: HR, 1.47 [0.63-3.47]) or in combination with immunomodulators (all-cause hospitalisation: HR, 0.70 [0.44-1.11]; CD-related hospitalisation: HR, 0.80 [0.42-1.52], abdominal surgery: HR, 1.02 [0.39-2.64]). CONCLUSIONS: In this population-based, propensity score matched, real-life cohort study using administrative claims, there was no significant difference in effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Singh S, Andersen NN, Andersson M, et al. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study. Aliment Pharmacol Ther. 2017. PMID: 29239001. doi:10.1111/apt.14466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。